GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cipla Ltd (OTCPK:CPLFY) » Definitions » Cyclically Adjusted PS Ratio

Cipla (CPLFY) Cyclically Adjusted PS Ratio : (As of May. 09, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Cipla Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cipla Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Cipla's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cipla Cyclically Adjusted PS Ratio Chart

Cipla Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.17 3.89 4.51 3.62

Cipla Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.40 3.62 3.95 4.52 4.65

Competitive Comparison of Cipla's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Cipla's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipla's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cipla's Cyclically Adjusted PS Ratio falls into.



Cipla Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Cipla's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Cipla's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.967/153.2548*153.2548
=0.967

Current CPI (Dec. 2023) = 153.2548.

Cipla Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.569 91.425 0.954
201406 0.551 94.103 0.897
201409 0.536 96.780 0.849
201412 0.520 96.780 0.823
201503 0.667 97.163 1.052
201506 0.731 99.841 1.122
201509 0.634 101.753 0.955
201512 0.574 102.901 0.855
201603 0.608 102.518 0.909
201606 0.656 105.961 0.949
201609 0.683 105.961 0.988
201612 0.652 105.196 0.950
201703 0.660 105.196 0.962
201706 0.660 107.109 0.944
201709 0.767 109.021 1.078
201712 0.741 109.404 1.038
201803 0.668 109.786 0.932
201806 0.703 111.317 0.968
201809 0.677 115.142 0.901
201812 0.684 115.142 0.910
201903 0.762 118.202 0.988
201906 0.696 120.880 0.882
201909 0.741 123.175 0.922
201912 0.737 126.235 0.895
202003 0.714 124.705 0.877
202006 0.700 127.000 0.845
202009 0.837 130.118 0.986
202012 0.867 130.889 1.015
202103 0.780 131.771 0.907
202106 0.921 134.084 1.053
202109 0.922 135.847 1.040
202112 0.894 138.161 0.992
202203 0.850 138.822 0.938
202206 0.843 142.347 0.908
202209 0.889 144.661 0.942
202212 0.860 145.763 0.904
202303 0.853 146.865 0.890
202306 0.944 150.280 0.963
202309 0.982 151.492 0.993
202312 0.967 153.255 0.967

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cipla  (OTCPK:CPLFY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Cipla Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Cipla's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cipla (CPLFY) Business Description

Traded in Other Exchanges
Address
Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large global presence. Cipla's growth strategy focuses on new product launches. It has two segments Pharmaceuticals and new ventures.

Cipla (CPLFY) Headlines

From GuruFocus

Cipla Files ANDA for Generic Version of GSK's Advair Diskus®

By PRNewswire PRNewswire 05-19-2020